This inventor holds 3 USPTO granted patents and 1 EPO patent. Top assignee: Universität Zu Lübeck. Active years: 2021-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021-2025
Title: Rosel Kretschmer-Kazemi Far: Innovator in Antisense Drug Development
Introduction
Rosel Kretschmer-Kazemi Far is a notable inventor based in Lübeck, Germany. He has made significant contributions to the field of medicine, particularly in the development of antisense drugs. With a total of 3 patents to his name, his work focuses on innovative solutions for treating inflammatory diseases.
Latest Patents
One of his latest patents is an antisense drug aimed at the human intercellular adhesion molecule 1 (ICAM-1). This invention also includes antisense drugs specifically designed for canines, targeting ICAM-1 to treat inflammation of the buccal cavity. The invention involves an isolated antisense oligonucleotide that can be used to prevent or treat inflammatory diseases in canine subjects. Additionally, it encompasses compositions or articles of manufacture that include this antisense oligonucleotide.
Career Highlights
Rosel Kretschmer-Kazemi Far is affiliated with the University of Lübeck, where he conducts his research and development work. His innovative approach to drug development has positioned him as a key figure in the field of medical research.
Collaborations
He has collaborated with notable colleagues, including Georg Sczakiel and Franziska Preuss, who contribute to his research endeavors.
Conclusion
Rosel Kretschmer-Kazemi Far's work in antisense drug development showcases his commitment to advancing medical treatments. His innovative patents reflect his expertise and dedication to improving health outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile